Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.
access to new drugs
A national formulary—essentially a list of drugs—is unlikely to match the comprehensive lists covered by private insurance plans.
Developing and testing new drugs costs a lot of money.
Profit incentivizes innovation and helps fund research and development.
Review board’s new reference countries have more limited access to new and innovative drugs.